HF Advisory Group LLC Sells 1,207 Shares of Cencora, Inc. $COR

Key Points

• HF Advisory Group LLC reduced its stake in Cencora, Inc. by 26.1% during the second quarter, now holding 3,409 shares valued at approximately $1,022,000.
• Cencora reported $4.00 EPS for the last quarter, exceeding estimates, with revenue of $80.66 billion reflecting an 8.7% increase year-over-year.
• The company announced a quarterly dividend of $0.55 per share, resulting in an annual yield of 0.8% with a payout ratio of 22.63%.

HF Advisory Group LLC reduced its stake in shares of Cencora, Inc. (NYSE:COR - Free Report) by 26.1% in the second quarter, according to its most recent filing with the SEC. The fund owned 3,409 shares of the company's stock after selling 1,207 shares during the period. HF Advisory Group LLC's holdings in Cencora were worth $1,022,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Cornerstone Planning Group LLC raised its position in Cencora by 106.7% during the first quarter. Cornerstone Planning Group LLC now owns 93 shares of the company's stock valued at $26,000 after purchasing an additional 48 shares in the last quarter. Hoey Investments Inc. purchased a new position in shares of Cencora during the 1st quarter valued at about $28,000. Costello Asset Management INC purchased a new position in shares of Cencora during the 1st quarter valued at about $28,000. University of Texas Texas AM Investment Management Co. purchased a new position in shares of Cencora during the 1st quarter valued at about $39,000. Finally, Vermillion Wealth Management Inc. purchased a new position in shares of Cencora during the 4th quarter valued at about $38,000. Hedge funds and other institutional investors own 97.52% of the company's stock.

Cencora Trading Down 0.2%

Shares of COR stock traded down $0.52 during trading hours on Friday, reaching $290.32. The company's stock had a trading volume of 7,182,669 shares, compared to its average volume of 1,405,903. The stock has a market capitalization of $56.29 billion, a P/E ratio of 29.87, a P/E/G ratio of 1.38 and a beta of 0.62. Cencora, Inc. has a one year low of $218.65 and a one year high of $309.35. The firm's fifty day simple moving average is $292.42 and its 200 day simple moving average is $287.06. The company has a current ratio of 0.90, a quick ratio of 0.53 and a debt-to-equity ratio of 3.64.

Cencora (NYSE:COR - Get Free Report) last issued its quarterly earnings data on Wednesday, August 6th. The company reported $4.00 earnings per share for the quarter, topping analysts' consensus estimates of $3.79 by $0.21. The firm had revenue of $80.66 billion for the quarter, compared to analyst estimates of $80.34 billion. Cencora had a return on equity of 267.36% and a net margin of 0.60%.The business's quarterly revenue was up 8.7% compared to the same quarter last year. During the same period last year, the company earned $3.34 EPS. Equities research analysts expect that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, September 3rd. Stockholders of record on Friday, August 15th were given a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.8%. The ex-dividend date was Friday, August 15th. Cencora's dividend payout ratio (DPR) is currently 22.63%.

Insider Activity at Cencora

In related news, Chairman Steven H. Collis sold 31,350 shares of Cencora stock in a transaction that occurred on Tuesday, September 16th. The stock was sold at an average price of $289.86, for a total transaction of $9,087,111.00. Following the sale, the chairman directly owned 305,913 shares in the company, valued at $88,671,942.18. The trade was a 9.30% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Robert P. Mauch sold 4,968 shares of Cencora stock in a transaction that occurred on Friday, July 18th. The shares were sold at an average price of $294.11, for a total value of $1,461,138.48. Following the sale, the chief executive officer owned 42,351 shares in the company, valued at $12,455,852.61. This represents a 10.50% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 65,475 shares of company stock worth $19,080,900 over the last 90 days. 10.80% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on COR shares. Wells Fargo & Company raised their price objective on Cencora from $337.00 to $354.00 and gave the company an "overweight" rating in a report on Wednesday, August 13th. Morgan Stanley set a $330.00 price objective on Cencora and gave the company an "equal weight" rating in a report on Wednesday, July 16th. Finally, Jefferies Financial Group raised their price objective on Cencora from $275.00 to $300.00 and gave the company a "hold" rating in a report on Monday, June 30th. Nine investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $311.25.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.